Mylan unveils Generic AXERT Tablets for acute treatment of migraine.
M2 EQUITYBITES-November 18, 2015-Mylan unveils Generic AXERT Tablets for acute treatment of migraine
(C)2015 M2 COMMUNICATIONS http://www.m2.com
Pharmaceutical company Mylan NV (Nasdaq:MYL) (TASE:MYL) reported on Tuesday the availability of Almotriptan Tablets USP, 6.25 mg and 12.5 mg in the US market.
The company added that the US Food and Drug Administration (FDA) approved Almotriptan Tablets USP, 6.25 mg and 12.5 mg, which is the generic version of Janssen Pharmaceutical's AXERT.
Almotriptan Tablets are used to treat patients with a history of migraine with or without aura. In adolescents age 12 to 17 years, it is indicated for the acute treatment of migraine headache pain in patients with a history of migraine attacks with or without aura usually lasting four hours or more (when untreated), said the company.
For the 12 months ending 30 September 2015, Almotriptan Tablets USP, 6.25 mg and 12.5 mg, had US sales of about USD29.2m, according to IMS Health.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Article Type:||Disease/Disorder overview|
|Date:||Nov 18, 2015|
|Previous Article:||Commercial National announces Q4 2015 dividend of USD0.26 per share.|
|Next Article:||Broadcom's board approves quarterly dividend of USD0.14 per share.|